<DOC>
	<DOCNO>NCT01848197</DOCNO>
	<brief_summary>RATIONALE : Adjuvant chemotherapy proven reduce significantly risk relapse death woman operable breast cancer.In North American Inter-Group factorial trial design ( CALGB 9741 ) concept dosedense adjuvant chemotherapy test patient node-positive breast cancer.Weekly paclitaxel standard adjuvant chemotherapy epirubicin cyclophosphamide improve disease-free overall survival woman breast cancer.Investigators ask dose-dense 2-week intertreatment interval ( support use granulocyte-colony stimulate factor ) well conventional inconvenient weekly interval .</brief_summary>
	<brief_title>Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week Adjuvant Treatment Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Age 1870 year female operable breast cancer patient 2 . Patients required register within 60 day final surgical procedure require adequately treat invasive primary tumor . 3. woman operable , histologically confirm adenocarcinoma breast a. histologically involved positive lymph node b. histologic diagnosis three negative patient ; c. lymph node negative , HER2 positive ( HER2 + + , FISH ( fluorescence situ hybridization method ) /CISH test confirm HER2 amplification positive ) , unable intolerant herceptin combine chemotherapy . 4 . Karnofsky point great equal 70 . 5 . Postmenopausal woman HCG test result negative , Women childbearing potential willing use effective contraception study . 6 . PATIENT CHARACTERISTICS : Hematopoietic : Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal TBIL great 1.5 time upper limit normal AKP great 2.5 time upper limit normal AST great 2.5 time upper limit normal ALT great 2.5 time upper limit normal Renal : Creatinine great 1.5 time upper limit normal Cardiovascular : No history myocardial infarction No congestive heart failure No significant ischemic valvular heart disease Other : No prior invasive malignancy within past 5 year except curatively treat basal squamous cell skin cancer carcinoma situ cervix No hypersensitivity paclitaxel docetaxel similarly formulate drug ( Cremophor polysorbate ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>